FDA Approval Activities for this Drug
Keppra (levetiracetam) Solution, UCB Pharma NDA 21-505 7/15/03 7/28/03
Keppra (levetiracetam) Tablets, UCB Pharma, NDA 21-035/S30 9/3/03 9/9/03
Keppra (levetiracetam) Tablets, UCB Pharma, NDA 21-035/S13 & S19 5/22/02 5/29/02
Keppra (levetiracetam) Tablets, 250 mg, 500 mg, and 750 mg. UCB Pharma, NDA 21-035 | Keppra (levetiracetam) Tablets, UCB Pharma, Inc., Labeling Revision
| Keppra (levetiracetam) Oral Solution, UCB Pharma, Inc., Labeling Revision | Keppra (levetiracetam) tablets, UCB Pharma, Patient Population Altered | Keppra (levetiracetam) oral solution, UCB Pharma, Patient Population Altered | Keppra (levetiracetam) tablets, UCB, Inc., Formulation Revision | Keppra (levetiracetam) tablets, UCB, Inc., Labeling Revision | Keppra (levetiracetam) oral solution, UCB, Inc., Labeling Revision | Keppra (Levetiracetam) Injection, UCB, Inc., Approval | Keppra (levetiracetam) tablets, UCB, Inc., Labeling Revision | Keppra (levetiracetam) oral solution, UCB, Inc., Labeling Revision | Keppra (levetiracetam) Tablets, UCB Inc., New or Modified Indication | Keppra (levetiracetam) Oral Solution, UCB Inc., New or Modified Indication | Keppra (levetiracetam) Injection, UCB Inc., Labeling Revision | Keppra (levetiracetam) Tablets, UCB Inc., Labeling Revision | Keppra (levetiracetam) Oral Solution, UCB Inc., Labeling Revision | Keppra (levetiracetam) Injection, UCB, Inc., New or Modified Indication | Keppra XR (levetiracetam) Extended-Release Tablets, UCB, Inc., Approval | Levetiracetam Tablets, Mylan Pharmaceuticals Inc., Approval